All In Biotech

Drug Trial Radar · NCT03716115

Therapeutic Approaches to Malnutrition Enteropathy

Therapeutic Approaches to Malnutrition Enteropathy: Phase II Trials of Four Novel Interventions in Children in Zambia and Zimbabwe

Last checked: Nov 19, 2026Latest source record: Sep 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

125

Actual

Start

May 4, 2020

Primary completion

Apr 27, 2021

Study completion Apr 27, 2021

Sponsor

Lead sponsor
Queen Mary University of LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 59 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The TAME study will evaluate four new approaches which will be compared against the standard care currently in use in the treatment of malnutrition enteropathy in children with severe acute malnutrition. A high pathogen burden causes damage to the intestinal mucosa which exacerbates nutritional impairment and leads to further susceptibility to infection and impaired epithelial regeneration. Enteropathy is characterised by multiple epithelial breaches, microbial translocation from gut lumen to systemic circulation and systemic inflammation.The trial will evaluate the potential impact of four interventions (colostrum, N-acetyl glucosamine, teduglutide, and budesonide) given for 14 days, which aim at mucosal restoration. The trial will determine if repairing damage to the small intestinal mucosa leads to the reduction of systemic inflammation and thus lessening the nutritional impairment, and so if this contributes to the reduction of mortality in children. In Zambia only, endoscopic biopsies and confocal laser endomicroscopy will be used to evaluate response and confirm safety at a mucosal level. Identifying an agent or agents which contribute most to mucosal healing will then ultimately lead to further large phase 3 trial in which the agent(s) will be further evaluated. The trial also anticipates to gain a more in depth understanding of pathophysiology and may identify where current management strategies of treating malnutrition enteropathy in children are failing.

Conditions

  • Severe Acute Malnutrition

Interventions

  • Colostrum high protein powder (Neovite)Dietary supplement

    Bovine colostrum provided as powder will be reconstituted and administered orally or via NG tube.

  • N-Acetyl Glucosamine (GInNAC)Drug

    N-Acetyl glucosamine provided as powder will be reconstituted and administered orally or via NG tube.

  • TeduglutideDrug

    Teduglutide will be administered daily as subcutaneous injection

  • BudesonideDrug

    Budesonide liquid (as marketed for nebulisation) will be administered orally or bia NG tube daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite measure of concentration of three faecal inflammatory markersTime frame: 14-18 days

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • University Teaching Hospital, Nationalist Road

    Lusaka, Zambia

  • Harare Central Hospital

    Harare, Zimbabwe

  • Parirenyatwa Hospital

    Harare, Zimbabwe

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.